Japan to buy 1.4 mln doses of Daiichi Sankyo COVID vaccine
The purchase is contingent on approval of the shot formulated for the XBB.1.5 Omicron subvariant of the virus. An earlier version of the mRNA-based vaccine was approved in August as a booster, becoming Japan's first home-grown shot for the coronavirus. During the pandemic, Japan mainly relied on imports of mRNA-type vaccines developed by U.S. drugmakers Pfizer and Moderna.
- Country:
- Japan
Japan's health ministry said on Friday it agreed to buy 1.4 million doses of Daiichi Sankyo's updated COVID-19 vaccine. The purchase is contingent on approval of the shot formulated for the XBB.1.5 Omicron subvariant of the virus.
An earlier version of the mRNA-based vaccine was approved in August as a booster, becoming Japan's first home-grown shot for the coronavirus. During the pandemic, Japan mainly relied on imports of mRNA-type vaccines developed by U.S. drugmakers Pfizer and Moderna.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- Pfizer
- Moderna
- Japan
- U.S.
- Omicron
- health ministry
- Daiichi Sankyo's
- COVID-19
Advertisement
ALSO READ
Japanese PM Fumio Kishida's Final U.S. Trip Amid Political Transitions
Japanese PM Fumio Kishida's Final U.S. Visit Plans
Top Players Withdraw from U.S. Open Due to Injuries
Outgoing Japanese PM Fumio Kishida Plans U.S. Visit for U.N. General Assembly
South Korea, Japan, and U.S. Reaffirm Trilateral Cooperation
Google News